MedTrace Logo

B-PaLMZ for TB Meningitis

NCT07227779 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-07-30

No results posted yet for this study

Summary

This two-stage study will compare consented research participants with tuberculous meningitis receiving BPaLMZ to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE.

Conditions

Interventions

DRUG

BPaLMZ Regimen

bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide

Sponsors & Collaborators

  • Infectious Diseases Institute, Uganda

    collaborator OTHER

  • University of Minnesota

    collaborator OTHER

  • Brighton & Sussex Medical School

    collaborator OTHER

  • Mbarara University of Science and Technology

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • Meningitis Foundation

    collaborator UNKNOWN

  • David Boulware

    lead OTHER

Principal Investigators

  • David Boulware, MD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-28
Primary Completion
2028-03-31
Completion
2030-09-30
FDA Drug
Yes

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07227779 on ClinicalTrials.gov